Urothelial Cancer

============================================================================

Patients characteristics

============================================================================

Treated patients characteristics

	PreIO (N=90)	PosIO (N=116)	Total (N=206)
Edad
Mean (SD)	71.1 (10.0)	68.3 (8.99)	69.5 (9.54)
Median [Min, Max]	69.0 [39.0, 94.0]	68.0 [49.0, 87.0]	68.0 [39.0, 94.0]
Edad.1
<65	21 (23.3%)	42 (36.2%)	63 (30.6%)
≥65	69 (76.7%)	74 (63.8%)	143 (69.4%)
Sexo
Mujer	8 (8.9%)	20 (17.2%)	28 (13.6%)
Hombre	82 (91.1%)	96 (82.8%)	178 (86.4%)
TipoUroterial
Vejiga	70 (77.8%)	95 (81.9%)	165 (80.1%)
Vía Urinarias	20 (22.2%)	21 (18.1%)	41 (19.9%)
IQ2
No	28 (31.1%)	50 (43.1%)	78 (37.9%)
Si	62 (68.9%)	66 (56.9%)	128 (62.1%)
QTNA2
No	81 (90.0%)	101 (87.1%)	182 (88.3%)
Si	9 (10.0%)	15 (12.9%)	24 (11.7%)
Ady2
No	70 (77.8%)	96 (82.8%)	166 (80.6%)
Si	20 (22.2%)	20 (17.2%)	40 (19.4%)
Stage2
Local-Avanzado	1 (1.1%)	1 (0.9%)	2 (1.0%)
Avanzado	89 (98.9%)	115 (99.1%)	204 (99.0%)
DebutMet2
No	58 (64.4%)	72 (62.1%)	130 (63.1%)
Si	32 (35.6%)	44 (37.9%)	76 (36.9%)
APSuperf
Si	61 (67.8%)	76 (65.5%)	137 (66.5%)
No	29 (32.2%)	40 (34.5%)	69 (33.5%)
Loc.Mets
Ganglionar	34 (37.8%)	52 (44.8%)	86 (41.7%)
Hepatica	22 (24.4%)	20 (17.2%)	42 (20.4%)
Hueso	14 (15.6%)	29 (25.0%)	43 (20.9%)
Pulmon	19 (21.1%)	15 (12.9%)	34 (16.5%)
Missing	1 (1.1%)	0 (0%)	1 (0.5%)
Visc.Mets
No	34 (37.8%)	52 (44.8%)	86 (41.7%)
Si	55 (61.1%)	64 (55.2%)	119 (57.8%)
Missing	1 (1.1%)	0 (0%)	1 (0.5%)
Hepatic.Mets1
0	67 (74.4%)	96 (82.8%)	163 (79.1%)
1	22 (24.4%)	20 (17.2%)	42 (20.4%)
Missing	1 (1.1%)	0 (0%)	1 (0.5%)
EC2.1
No	67 (74.4%)	77 (66.4%)	144 (69.9%)
Si	23 (25.6%)	39 (33.6%)	62 (30.1%)
Linea1
No	0 (0%)	0 (0%)	0 (0%)
Si	90 (100%)	116 (100%)	206 (100%)
Linea2
No	49 (54.4%)	59 (50.9%)	108 (52.4%)
Si	41 (45.6%)	57 (49.1%)	98 (47.6%)
Linea3
No	65 (72.2%)	87 (75.0%)	152 (73.8%)
Si	25 (27.8%)	29 (25.0%)	54 (26.2%)
Linea4
No	85 (94.4%)	109 (94.0%)	194 (94.2%)
Si	5 (5.6%)	7 (6.0%)	12 (5.8%)
OSL1fu0
OS <1y	41 (45.6%)	57 (49.1%)	98 (47.6%)
OS ≥1y	49 (54.4%)	59 (50.9%)	108 (52.4%)
OSL1fu2
OS <2y	58 (64.4%)	89 (76.7%)	147 (71.4%)
OS ≥2y	32 (35.6%)	27 (23.3%)	59 (28.6%)
PFSL1fu1
PFSL1 <1y	62 (68.9%)	88 (75.9%)	150 (72.8%)
PFSL1 ≥1y	27 (30.0%)	28 (24.1%)	55 (26.7%)
Missing	1 (1.1%)	0 (0%)	1 (0.5%)
PFSL1fu2
PFSL1 <2y	71 (78.9%)	105 (90.5%)	176 (85.4%)
PFSL1 ≥2y	18 (20.0%)	11 (9.5%)	29 (14.1%)
Missing	1 (1.1%)	0 (0%)	1 (0.5%)
PFSL2fu1
PFSL2 <1y	35 (38.9%)	49 (42.2%)	84 (40.8%)
PFSL2 ≥1y	6 (6.7%)	6 (5.2%)	12 (5.8%)
Missing	49 (54.4%)	61 (52.6%)	110 (53.4%)
PFSL2fu2
PFSL2 <2y	41 (45.6%)	53 (45.7%)	94 (45.6%)
PFSL2 ≥2y	0 (0%)	2 (1.7%)	2 (1.0%)
Missing	49 (54.4%)	61 (52.6%)	110 (53.4%)

EpocaIO
	PreIO	PosIO	p
n	90	116
Edad (mean (SD))	71.12 (10.04)	68.31 (8.99)	0.036
Edad.1 = ≥65 (%)	69 ( 76.7)	74 ( 63.8)	0.066
Edad.2 (%)			0.083
<65	21 ( 23.3)	42 ( 36.2)
65-85	61 ( 67.8)	69 ( 59.5)
≥85	8 ( 8.9)	5 ( 4.3)
Sexo = Hombre (%)	82 ( 91.1)	96 ( 82.8)	0.126
TipoUroterial = Vía Urinarias (%)	20 ( 22.2)	21 ( 18.1)	0.577
IQ2 = Si (%)	62 ( 68.9)	66 ( 56.9)	0.106
QTNA2 = Si (%)	9 ( 10.0)	15 ( 12.9)	0.666
Ady2 = Si (%)	20 ( 22.2)	20 ( 17.2)	0.472
Loc.Mets (%)			0.106
Ganglionar	34 ( 38.2)	52 ( 44.8)
Hepatica	22 ( 24.7)	20 ( 17.2)
Hueso	14 ( 15.7)	29 ( 25.0)
Pulmon	19 ( 21.3)	15 ( 12.9)
Visc.Mets = Si (%)	55 ( 61.8)	64 ( 55.2)	0.418
Hepatic.Mets1 = 1 (%)	22 ( 24.7)	20 ( 17.2)	0.254
DebutMet2 = Si (%)	32 ( 35.6)	44 ( 37.9)	0.838
APSuperf = No (%)	29 ( 32.2)	40 ( 34.5)	0.848
EC2.1 = Si (%)	23 ( 25.6)	39 ( 33.6)	0.272
Linea1 = Si (%)	90 (100.0)	116 (100.0)	NaN
Linea2 = Si (%)	41 ( 45.6)	57 ( 49.1)	0.711
Linea3 = Si (%)	25 ( 27.8)	29 ( 25.0)	0.772
Linea4 = Si (%)	5 ( 5.6)	7 ( 6.0)	1.000
OSL1fu0 = OS ≥1y (%)	49 ( 54.4)	59 ( 50.9)	0.711
OSL1fu2 = OS ≥2y (%)	32 ( 35.6)	27 ( 23.3)	0.075
PFSL1fu1 = PFSL1 ≥1y (%)	27 ( 30.3)	28 ( 24.1)	0.404
PFSL1fu2 = PFSL1 ≥2y (%)	18 ( 20.2)	11 ( 9.5)	0.047
PFSL2fu1 = PFSL2 ≥1y (%)	6 ( 14.6)	6 ( 10.9)	0.815
PFSL2fu2 = PFSL2 ≥2y (%)	0 ( 0.0)	2 ( 3.6)	0.609

============================================================================

Medianas de supervivencia (meses)

============================================================================

Median follow-up times

median follow-up overall

## Quantiles of the potential follow up time distribution based on the Kaplan-Meier method 
## applied to the censored times reversing the roles of event status and censored.
## 
## Table of quantiles and corresponding confidence limits:
##      q quantile lower upper
## 1 0.00       NA    NA    NA
## 2 0.25   131.68 67.98 180.0
## 3 0.50    48.62 39.29  68.0
## 4 0.75    21.19 13.83  31.0
## 5 1.00     0.43  0.43   2.7
## Median time (IQR):48.62 (21.19;131.68)

median follow-up survivors

## Quantiles of the potential follow up time distribution based on the Kaplan-Meier method 
## applied to the censored times reversing the roles of event status and censored.
## 
## Table of quantiles and corresponding confidence limits:
##      q quantile lower upper
## 1 0.00       NA    NA    NA
## 2 0.25    40.08 26.38  56.6
## 3 0.50    15.93  9.53  25.8
## 4 0.75     6.41  5.85   8.6
## 5 1.00     0.43  0.43   2.7
## Median time (IQR):15.93 (6.41;40.08)

median follow-up Pre-IO

## Quantiles of the potential follow up time distribution based on the Kaplan-Meier method 
## applied to the censored times reversing the roles of event status and censored.
## 
## Table of quantiles and corresponding confidence limits:
##      q quantile lower upper
## 1 0.00       NA    NA    NA
## 2 0.25      181   178    NA
## 3 0.50      178   103   181
## 4 0.75      103    68   178
## 5 1.00       68    68   103
## Median time (IQR):177.74 (103.36;181.03)

median follow-up Post-IO

## Quantiles of the potential follow up time distribution based on the Kaplan-Meier method 
## applied to the censored times reversing the roles of event status and censored.
## 
## Table of quantiles and corresponding confidence limits:
##      q quantile lower upper
## 1 0.00       NA    NA    NA
## 2 0.25     42.8  33.3  56.6
## 3 0.50     27.2  21.2  39.3
## 4 0.75     13.6   8.6  18.6
## 5 1.00      1.6   1.6   3.3
## Median time (IQR):27.17 (13.57;42.84)

============================================================================

Análisis Primera Linea

============================================================================

Resumen

	PreIO (N=90)	PosIO (N=116)	Total (N=206)
Tratamiento de 1º linea
BSC	0 (0%)	0 (0%)	0 (0%)
CBCDA-based	46 (51.1%)	56 (48.3%)	102 (49.5%)
CDDP-based	33 (36.7%)	32 (27.6%)	65 (31.6%)
IO	0 (0%)	21 (18.1%)	21 (10.2%)
QT no-platino	11 (12.2%)	7 (6.0%)	18 (8.7%)
Nro. Ciclos de 1º linea
1-3	20 (22.2%)	30 (25.9%)	50 (24.3%)
4-6	63 (70.0%)	71 (61.2%)	134 (65.0%)
>6	6 (6.7%)	13 (11.2%)	19 (9.2%)
Missing	1 (1.1%)	2 (1.7%)	3 (1.5%)
Respuesta a 1º linea
EE	16 (17.8%)	25 (21.6%)	41 (19.9%)
PD	29 (32.2%)	30 (25.9%)	59 (28.6%)
RC	17 (18.9%)	21 (18.1%)	38 (18.4%)
RP	26 (28.9%)	37 (31.9%)	63 (30.6%)
Missing	2 (2.2%)	3 (2.6%)	5 (2.4%)
ORR
No	45 (50.0%)	55 (47.4%)	100 (48.5%)
Si	43 (47.8%)	58 (50.0%)	101 (49.0%)
Missing	2 (2.2%)	3 (2.6%)	5 (2.4%)
DCR
No	29 (32.2%)	30 (25.9%)	59 (28.6%)
Si	59 (65.6%)	83 (71.6%)	142 (68.9%)
Missing	2 (2.2%)	3 (2.6%)	5 (2.4%)
OSL1m
Mean (SD)	34.2 (46.9)	15.9 (13.2)	23.9 (33.7)
Median [Min, Max]	14.4 [0.427, 197]	12.3 [0.526, 66.0]	12.8 [0.427, 197]
PFSL1m
Mean (SD)	23.1 (42.1)	10.9 (12.6)	16.2 (29.8)
Median [Min, Max]	7.26 [0.427, 197]	6.78 [0.131, 66.0]	7.13 [0.131, 197]
Missing	1 (1.1%)	0 (0%)	1 (0.5%)
OSL1fu3
OS <3y	69 (76.7%)	106 (91.4%)	175 (85.0%)
OS ≥3y	21 (23.3%)	10 (8.6%)	31 (15.0%)
OSL1fu
OS <2y	58 (64.4%)	89 (76.7%)	147 (71.4%)
OS 2-5y	17 (18.9%)	26 (22.4%)	43 (20.9%)
OS ≥5y	15 (16.7%)	1 (0.9%)	16 (7.8%)
OSL1fu0
OS <1y	41 (45.6%)	57 (49.1%)	98 (47.6%)
OS ≥1y	49 (54.4%)	59 (50.9%)	108 (52.4%)
OSL1fu2
OS <2y	58 (64.4%)	89 (76.7%)	147 (71.4%)
OS ≥2y	32 (35.6%)	27 (23.3%)	59 (28.6%)

EpocaIO
	PreIO	PosIO	p
n	90	116
N.ciclos12 (%)			0.366
1-3	20 (22.5)	30 (26.3)
4-6	63 (70.8)	71 (62.3)
>6	6 ( 6.7)	13 (11.4)
Respuesta1 (%)			0.742
EE	16 (18.2)	25 (22.1)
PD	29 (33.0)	30 (26.5)
RC	17 (19.3)	21 (18.6)
RP	26 (29.5)	37 (32.7)
ORR1 = Si (%)	43 (48.9)	58 (51.3)	0.838
DCR1 = Si (%)	59 (67.0)	83 (73.5)	0.405
OSL1m (mean (SD))	34.22 (46.90)	15.95 (13.24)	<0.001
PFSL1m (mean (SD))	23.14 (42.10)	10.94 (12.62)	0.003
OSL1fu3 = OS ≥3y (%)	21 (23.3)	10 ( 8.6)	0.006
OSL1fu0 = OS ≥1y (%)	49 (54.4)	59 (50.9)	0.711
OSL1fu2 = OS ≥2y (%)	32 (35.6)	27 (23.3)	0.075

Respuesta L1 : all categories

All L1

	CBCDA-based (N=102)	CDDP-based (N=65)	IO (N=21)	QT no-platino (N=18)	Total (N=206)
Respuesta a 1º linea
EE	20 (19.6%)	13 (20.0%)	6 (28.6%)	2 (11.1%)	41 (19.9%)
PD	24 (23.5%)	16 (24.6%)	8 (38.1%)	11 (61.1%)	59 (28.6%)
RC	15 (14.7%)	16 (24.6%)	3 (14.3%)	4 (22.2%)	38 (18.4%)
RP	38 (37.3%)	20 (30.8%)	4 (19.0%)	1 (5.6%)	63 (30.6%)
Missing	5 (4.9%)	0 (0%)	0 (0%)	0 (0%)	5 (2.4%)
ORR
No	44 (43.1%)	29 (44.6%)	14 (66.7%)	13 (72.2%)	100 (48.5%)
Si	53 (52.0%)	36 (55.4%)	7 (33.3%)	5 (27.8%)	101 (49.0%)
Missing	5 (4.9%)	0 (0%)	0 (0%)	0 (0%)	5 (2.4%)
DCR
No	24 (23.5%)	16 (24.6%)	8 (38.1%)	11 (61.1%)	59 (28.6%)
Si	73 (71.6%)	49 (75.4%)	13 (61.9%)	7 (38.9%)	142 (68.9%)
Missing	5 (4.9%)	0 (0%)	0 (0%)	0 (0%)	5 (2.4%)
OSL1fu0
OS <1y	52 (51.0%)	24 (36.9%)	10 (47.6%)	12 (66.7%)	98 (47.6%)
OS ≥1y	50 (49.0%)	41 (63.1%)	11 (52.4%)	6 (33.3%)	108 (52.4%)
OSL1fu2
OS <2y	76 (74.5%)	41 (63.1%)	17 (81.0%)	13 (72.2%)	147 (71.4%)
OS ≥2y	26 (25.5%)	24 (36.9%)	4 (19.0%)	5 (27.8%)	59 (28.6%)
PFSL1fu1
PFSL1 <1y	81 (79.4%)	41 (63.1%)	16 (76.2%)	12 (66.7%)	150 (72.8%)
PFSL1 ≥1y	20 (19.6%)	24 (36.9%)	5 (23.8%)	6 (33.3%)	55 (26.7%)
Missing	1 (1.0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.5%)
PFSL1fu2
PFSL1 <2y	90 (88.2%)	54 (83.1%)	18 (85.7%)	14 (77.8%)	176 (85.4%)
PFSL1 ≥2y	11 (10.8%)	11 (16.9%)	3 (14.3%)	4 (22.2%)	29 (14.1%)
Missing	1 (1.0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.5%)

Pre-IO L1

	CBCDA-based (N=46)	CDDP-based (N=33)	QT no-platino (N=11)	Total (N=90)
Respuesta1
EE	9 (19.6%)	5 (15.2%)	2 (18.2%)	16 (17.8%)
PD	13 (28.3%)	11 (33.3%)	5 (45.5%)	29 (32.2%)
RC	5 (10.9%)	9 (27.3%)	3 (27.3%)	17 (18.9%)
RP	17 (37.0%)	8 (24.2%)	1 (9.1%)	26 (28.9%)
Missing	2 (4.3%)	0 (0%)	0 (0%)	2 (2.2%)
ORR1
No	22 (47.8%)	16 (48.5%)	7 (63.6%)	45 (50.0%)
Si	22 (47.8%)	17 (51.5%)	4 (36.4%)	43 (47.8%)
Missing	2 (4.3%)	0 (0%)	0 (0%)	2 (2.2%)
DCR1
No	13 (28.3%)	11 (33.3%)	5 (45.5%)	29 (32.2%)
Si	31 (67.4%)	22 (66.7%)	6 (54.5%)	59 (65.6%)
Missing	2 (4.3%)	0 (0%)	0 (0%)	2 (2.2%)

Pos-IO L1

	CBCDA-based (N=56)	CDDP-based (N=32)	IO (N=21)	QT no-platino (N=7)	Total (N=116)
Respuesta1
EE	11 (19.6%)	8 (25.0%)	6 (28.6%)	0 (0%)	25 (21.6%)
PD	11 (19.6%)	5 (15.6%)	8 (38.1%)	6 (85.7%)	30 (25.9%)
RC	10 (17.9%)	7 (21.9%)	3 (14.3%)	1 (14.3%)	21 (18.1%)
RP	21 (37.5%)	12 (37.5%)	4 (19.0%)	0 (0%)	37 (31.9%)
Missing	3 (5.4%)	0 (0%)	0 (0%)	0 (0%)	3 (2.6%)
ORR1
No	22 (39.3%)	13 (40.6%)	14 (66.7%)	6 (85.7%)	55 (47.4%)
Si	31 (55.4%)	19 (59.4%)	7 (33.3%)	1 (14.3%)	58 (50.0%)
Missing	3 (5.4%)	0 (0%)	0 (0%)	0 (0%)	3 (2.6%)
DCR1
No	11 (19.6%)	5 (15.6%)	8 (38.1%)	6 (85.7%)	30 (25.9%)
Si	42 (75.0%)	27 (84.4%)	13 (61.9%)	1 (14.3%)	83 (71.6%)
Missing	3 (5.4%)	0 (0%)	0 (0%)	0 (0%)	3 (2.6%)

Respuesta L1 : platinum

All L1

	IO (N=21)	Platino (N=167)	QT no-platino (N=18)	Total (N=206)
Respuesta a 1º linea
EE	6 (28.6%)	33 (19.8%)	2 (11.1%)	41 (19.9%)
PD	8 (38.1%)	40 (24.0%)	11 (61.1%)	59 (28.6%)
RC	3 (14.3%)	31 (18.6%)	4 (22.2%)	38 (18.4%)
RP	4 (19.0%)	58 (34.7%)	1 (5.6%)	63 (30.6%)
Missing	0 (0%)	5 (3.0%)	0 (0%)	5 (2.4%)
ORR
No	14 (66.7%)	73 (43.7%)	13 (72.2%)	100 (48.5%)
Si	7 (33.3%)	89 (53.3%)	5 (27.8%)	101 (49.0%)
Missing	0 (0%)	5 (3.0%)	0 (0%)	5 (2.4%)
DCR
No	8 (38.1%)	40 (24.0%)	11 (61.1%)	59 (28.6%)
Si	13 (61.9%)	122 (73.1%)	7 (38.9%)	142 (68.9%)
Missing	0 (0%)	5 (3.0%)	0 (0%)	5 (2.4%)
OSL1fu0
OS <1y	10 (47.6%)	76 (45.5%)	12 (66.7%)	98 (47.6%)
OS ≥1y	11 (52.4%)	91 (54.5%)	6 (33.3%)	108 (52.4%)
OSL1fu2
OS <2y	17 (81.0%)	117 (70.1%)	13 (72.2%)	147 (71.4%)
OS ≥2y	4 (19.0%)	50 (29.9%)	5 (27.8%)	59 (28.6%)
PFSL1fu1
PFSL1 <1y	16 (76.2%)	122 (73.1%)	12 (66.7%)	150 (72.8%)
PFSL1 ≥1y	5 (23.8%)	44 (26.3%)	6 (33.3%)	55 (26.7%)
Missing	0 (0%)	1 (0.6%)	0 (0%)	1 (0.5%)
PFSL1fu2
PFSL1 <2y	18 (85.7%)	144 (86.2%)	14 (77.8%)	176 (85.4%)
PFSL1 ≥2y	3 (14.3%)	22 (13.2%)	4 (22.2%)	29 (14.1%)
Missing	0 (0%)	1 (0.6%)	0 (0%)	1 (0.5%)

Pre-IO L1

	Platino (N=79)	QT no-platino (N=11)	Total (N=90)
Respuesta1
EE	14 (17.7%)	2 (18.2%)	16 (17.8%)
PD	24 (30.4%)	5 (45.5%)	29 (32.2%)
RC	14 (17.7%)	3 (27.3%)	17 (18.9%)
RP	25 (31.6%)	1 (9.1%)	26 (28.9%)
Missing	2 (2.5%)	0 (0%)	2 (2.2%)
ORR1
No	38 (48.1%)	7 (63.6%)	45 (50.0%)
Si	39 (49.4%)	4 (36.4%)	43 (47.8%)
Missing	2 (2.5%)	0 (0%)	2 (2.2%)
DCR1
No	24 (30.4%)	5 (45.5%)	29 (32.2%)
Si	53 (67.1%)	6 (54.5%)	59 (65.6%)
Missing	2 (2.5%)	0 (0%)	2 (2.2%)

Pos-IO L1

	IO (N=21)	Platino (N=88)	QT no-platino (N=7)	Total (N=116)
Respuesta1
EE	6 (28.6%)	19 (21.6%)	0 (0%)	25 (21.6%)
PD	8 (38.1%)	16 (18.2%)	6 (85.7%)	30 (25.9%)
RC	3 (14.3%)	17 (19.3%)	1 (14.3%)	21 (18.1%)
RP	4 (19.0%)	33 (37.5%)	0 (0%)	37 (31.9%)
Missing	0 (0%)	3 (3.4%)	0 (0%)	3 (2.6%)
ORR1
No	14 (66.7%)	35 (39.8%)	6 (85.7%)	55 (47.4%)
Si	7 (33.3%)	50 (56.8%)	1 (14.3%)	58 (50.0%)
Missing	0 (0%)	3 (3.4%)	0 (0%)	3 (2.6%)
DCR1
No	8 (38.1%)	16 (18.2%)	6 (85.7%)	30 (25.9%)
Si	13 (61.9%)	69 (78.4%)	1 (14.3%)	83 (71.6%)
Missing	0 (0%)	3 (3.4%)	0 (0%)	3 (2.6%)

Tratamiento de 1ra linea

Pre-IO L1

	CBCDA-based (N=46)	CDDP-based (N=33)	QT no-platino (N=11)	Total (N=90)
Primera.linea
CBCDA/GEM	40 (87.0%)	0 (0%)	0 (0%)	40 (44.4%)
CBCDA/GEM/OGX	1 (2.2%)	0 (0%)	0 (0%)	1 (1.1%)
CBCDA/GEM/TAXOL	1 (2.2%)	0 (0%)	0 (0%)	1 (1.1%)
CBCDA/TAXOL	3 (6.5%)	0 (0%)	0 (0%)	3 (3.3%)
CBCDA/VP16	1 (2.2%)	0 (0%)	0 (0%)	1 (1.1%)
CDDP/GEM	0 (0%)	24 (72.7%)	0 (0%)	24 (26.7%)
CDDP/GEM/DOVITINIB	0 (0%)	1 (3.0%)	0 (0%)	1 (1.1%)
CDDP/GEM/ERIBULINA	0 (0%)	1 (3.0%)	0 (0%)	1 (1.1%)
CDDP/LAROTAXEL	0 (0%)	3 (9.1%)	0 (0%)	3 (3.3%)
CDDP/PEME	0 (0%)	2 (6.1%)	0 (0%)	2 (2.2%)
MVAC	0 (0%)	2 (6.1%)	0 (0%)	2 (2.2%)
CABAZITAXEL	0 (0%)	0 (0%)	1 (9.1%)	1 (1.1%)
GEM	0 (0%)	0 (0%)	7 (63.6%)	7 (7.8%)
GEM/TAXOL	0 (0%)	0 (0%)	3 (27.3%)	3 (3.3%)

	Platino (N=79)	QT no-platino (N=11)	Total (N=90)
Primera.linea
CBCDA/GEM	40 (50.6%)	0 (0%)	40 (44.4%)
CBCDA/GEM/OGX	1 (1.3%)	0 (0%)	1 (1.1%)
CBCDA/GEM/TAXOL	1 (1.3%)	0 (0%)	1 (1.1%)
CBCDA/TAXOL	3 (3.8%)	0 (0%)	3 (3.3%)
CBCDA/VP16	1 (1.3%)	0 (0%)	1 (1.1%)
CDDP/GEM	24 (30.4%)	0 (0%)	24 (26.7%)
CDDP/GEM/DOVITINIB	1 (1.3%)	0 (0%)	1 (1.1%)
CDDP/GEM/ERIBULINA	1 (1.3%)	0 (0%)	1 (1.1%)
CDDP/LAROTAXEL	3 (3.8%)	0 (0%)	3 (3.3%)
CDDP/PEME	2 (2.5%)	0 (0%)	2 (2.2%)
MVAC	2 (2.5%)	0 (0%)	2 (2.2%)
CABAZITAXEL	0 (0%)	1 (9.1%)	1 (1.1%)
GEM	0 (0%)	7 (63.6%)	7 (7.8%)
GEM/TAXOL	0 (0%)	3 (27.3%)	3 (3.3%)

Pos-IO L1

	CBCDA-based (N=56)	CDDP-based (N=32)	IO (N=21)	QT no-platino (N=7)	Total (N=116)
Primera.linea
ATEZO/CBCDA/GEM	2 (3.6%)	0 (0%)	0 (0%)	0 (0%)	2 (1.7%)
CBCDA/AUC	1 (1.8%)	0 (0%)	0 (0%)	0 (0%)	1 (0.9%)
CBCDA/GEM	51 (91.1%)	0 (0%)	0 (0%)	0 (0%)	51 (44.0%)
CBCDA/TAXOL	1 (1.8%)	0 (0%)	0 (0%)	0 (0%)	1 (0.9%)
CBCDA/VP16	1 (1.8%)	0 (0%)	0 (0%)	0 (0%)	1 (0.9%)
ATEZO/CDDP/GEM	0 (0%)	1 (3.1%)	0 (0%)	0 (0%)	1 (0.9%)
CDDP/GEM	0 (0%)	29 (90.6%)	0 (0%)	0 (0%)	29 (25.0%)
CDDP/VP16	0 (0%)	1 (3.1%)	0 (0%)	0 (0%)	1 (0.9%)
NIVO/CDDP/GEM	0 (0%)	1 (3.1%)	0 (0%)	0 (0%)	1 (0.9%)
ATEZO	0 (0%)	0 (0%)	5 (23.8%)	0 (0%)	5 (4.3%)
DURVA	0 (0%)	0 (0%)	1 (4.8%)	0 (0%)	1 (0.9%)
NIVO/IPI	0 (0%)	0 (0%)	10 (47.6%)	0 (0%)	10 (8.6%)
PEMBRO	0 (0%)	0 (0%)	3 (14.3%)	0 (0%)	3 (2.6%)
PEMBRO/EMFORTUMAB	0 (0%)	0 (0%)	2 (9.5%)	0 (0%)	2 (1.7%)
DOCETAXEL	0 (0%)	0 (0%)	0 (0%)	1 (14.3%)	1 (0.9%)
GEM	0 (0%)	0 (0%)	0 (0%)	3 (42.9%)	3 (2.6%)
GEM/TAXOL	0 (0%)	0 (0%)	0 (0%)	1 (14.3%)	1 (0.9%)
VINFLUNINA	0 (0%)	0 (0%)	0 (0%)	2 (28.6%)	2 (1.7%)

	IO (N=21)	Platino (N=88)	QT no-platino (N=7)	Total (N=116)
Primera.linea
ATEZO	5 (23.8%)	0 (0%)	0 (0%)	5 (4.3%)
DURVA	1 (4.8%)	0 (0%)	0 (0%)	1 (0.9%)
NIVO/IPI	10 (47.6%)	0 (0%)	0 (0%)	10 (8.6%)
PEMBRO	3 (14.3%)	0 (0%)	0 (0%)	3 (2.6%)
PEMBRO/EMFORTUMAB	2 (9.5%)	0 (0%)	0 (0%)	2 (1.7%)
ATEZO/CBCDA/GEM	0 (0%)	2 (2.3%)	0 (0%)	2 (1.7%)
ATEZO/CDDP/GEM	0 (0%)	1 (1.1%)	0 (0%)	1 (0.9%)
CBCDA/AUC	0 (0%)	1 (1.1%)	0 (0%)	1 (0.9%)
CBCDA/GEM	0 (0%)	51 (58.0%)	0 (0%)	51 (44.0%)
CBCDA/TAXOL	0 (0%)	1 (1.1%)	0 (0%)	1 (0.9%)
CBCDA/VP16	0 (0%)	1 (1.1%)	0 (0%)	1 (0.9%)
CDDP/GEM	0 (0%)	29 (33.0%)	0 (0%)	29 (25.0%)
CDDP/VP16	0 (0%)	1 (1.1%)	0 (0%)	1 (0.9%)
NIVO/CDDP/GEM	0 (0%)	1 (1.1%)	0 (0%)	1 (0.9%)
DOCETAXEL	0 (0%)	0 (0%)	1 (14.3%)	1 (0.9%)
GEM	0 (0%)	0 (0%)	3 (42.9%)	3 (2.6%)
GEM/TAXOL	0 (0%)	0 (0%)	1 (14.3%)	1 (0.9%)
VINFLUNINA	0 (0%)	0 (0%)	2 (28.6%)	2 (1.7%)

============================================================================

Overall Survival L1

============================================================================

OS L1 Todos Pre vs Pos IO

## Call: survfit(formula = Surv(OSL1m, Muerto) ~ EpocaIO, data = dbl1, 
##     type = "kaplan-meier")
## 
##                 n events median 0.95LCL 0.95UCL
## EpocaIO=PreIO  90     80   14.4    9.99    22.2
## EpocaIO=PosIO 116     69   17.7   14.55    25.8

OS L1 Pre IO

## Call: survfit(formula = Surv(OSL1m, Muerto) ~ L1Tx1, data = dbIO0, 
##     type = "kaplan-meier")
## 
##                      n events median 0.95LCL 0.95UCL
## L1Tx1=Platino       79     69  18.99   10.28    23.6
## L1Tx1=QT no-platino 11     11   7.69    5.06      NA

## Call: survfit(formula = Surv(OSL1m, Muerto) ~ L1Tx, data = dbIO0, type = "kaplan-meier")
## 
##                     n events median 0.95LCL 0.95UCL
## L1Tx=CBCDA-based   46     44  13.36    8.77    22.4
## L1Tx=CDDP-based    33     25  21.68   12.55    61.4
## L1Tx=QT no-platino 11     11   7.69    5.06      NA

OS L1 Pos IO

## Call: survfit(formula = Surv(OSL1m, Muerto) ~ L1Tx1, data = dbIO1, 
##     type = "kaplan-meier")
## 
##                      n events median 0.95LCL 0.95UCL
## L1Tx1=IO            21     12   14.9   10.48      NA
## L1Tx1=Platino       88     51   19.3   15.47    26.3
## L1Tx1=QT no-platino  7      6    4.5    2.14      NA

## Call: survfit(formula = Surv(OSL1m, Muerto) ~ L1Tx, data = dbIO1, type = "kaplan-meier")
## 
##                     n events median 0.95LCL 0.95UCL
## L1Tx=CBCDA-based   56     33   15.5   13.34    27.6
## L1Tx=CDDP-based    32     18   22.4   17.68      NA
## L1Tx=IO            21     12   14.9   10.48      NA
## L1Tx=QT no-platino  7      6    4.5    2.14      NA

============================================================================

Progresion Free Survival L1

============================================================================

Pre vs Pos IO

## Call: survfit(formula = Surv(PFSL1m, PFS1) ~ EpocaIO, data = dbl1, 
##     type = "kaplan-meier")
## 
##    2 observations deleted due to missingness 
##                 n events median 0.95LCL 0.95UCL
## EpocaIO=PreIO  89     81   7.26    5.95   10.12
## EpocaIO=PosIO 115     93   7.33    6.41    9.59

Pre IO

## Call: survfit(formula = Surv(PFSL1m, PFS1) ~ L1Tx1, data = dbIO0, type = "kaplan-meier")
## 
##    1 observation deleted due to missingness 
##                      n events median 0.95LCL 0.95UCL
## L1Tx1=Platino       78     70   7.33    6.44    10.7
## L1Tx1=QT no-platino 11     11   4.86    2.40      NA

## Call: survfit(formula = Surv(PFSL1m, PFS1) ~ L1Tx, data = dbIO0, type = "kaplan-meier")
## 
##    1 observation deleted due to missingness 
##                     n events median 0.95LCL 0.95UCL
## L1Tx=CBCDA-based   45     44   7.33    5.95    10.7
## L1Tx=CDDP-based    33     26   7.33    5.52    17.0
## L1Tx=QT no-platino 11     11   4.86    2.40      NA

Pos IO

## Call: survfit(formula = Surv(PFSL1m, PFS1) ~ L1Tx1, data = dbIO1, type = "kaplan-meier")
## 
##    1 observation deleted due to missingness 
##                      n events median 0.95LCL 0.95UCL
## L1Tx1=IO            21     13   6.93    3.68      NA
## L1Tx1=Platino       87     74   7.49    6.41    9.99
## L1Tx1=QT no-platino  7      6   3.52    1.45      NA

## Call: survfit(formula = Surv(PFSL1m, PFS1) ~ L1Tx, data = dbIO1, type = "kaplan-meier")
## 
##    1 observation deleted due to missingness 
##                     n events median 0.95LCL 0.95UCL
## L1Tx=CBCDA-based   55     49   6.64    5.91     9.0
## L1Tx=CDDP-based    32     25   9.59    8.11    13.2
## L1Tx=IO            21     13   6.93    3.68      NA
## L1Tx=QT no-platino  7      6   3.52    1.45      NA

============================================================================

Análisis Segunda Linea

============================================================================

Resumen

	PreIO (N=41)	PosIO (N=57)	Total (N=98)
Tratamiento de 2º linea
CBCDA-based	11 (26.8%)	9 (15.8%)	20 (20.4%)
CDDP-based	13 (31.7%)	6 (10.5%)	19 (19.4%)
IO	0 (0%)	33 (57.9%)	33 (33.7%)
QT no-platino	16 (39.0%)	5 (8.8%)	21 (21.4%)
Target	1 (2.4%)	4 (7.0%)	5 (5.1%)
Nro. Ciclos de 2º linea
1-3	17 (41.5%)	19 (33.3%)	36 (36.7%)
4-6	19 (46.3%)	25 (43.9%)	44 (44.9%)
>6	4 (9.8%)	10 (17.5%)	14 (14.3%)
Missing	1 (2.4%)	3 (5.3%)	4 (4.1%)
Respuesta a 2º linea
EE	8 (19.5%)	14 (24.6%)	22 (22.4%)
PD	20 (48.8%)	25 (43.9%)	45 (45.9%)
RC	4 (9.8%)	4 (7.0%)	8 (8.2%)
RP	9 (22.0%)	11 (19.3%)	20 (20.4%)
Missing	0 (0%)	3 (5.3%)	3 (3.1%)
OSL2m
Mean (SD)	20.6 (34.4)	9.28 (8.95)	14.1 (24.0)
Median [Min, Max]	11.3 [0.526, 165]	5.88 [0.361, 45.1]	7.79 [0.361, 165]
Missing	0 (0%)	2 (3.5%)	2 (2.0%)
ORR2
No	28 (68.3%)	39 (68.4%)	67 (68.4%)
Si	13 (31.7%)	15 (26.3%)	28 (28.6%)
Missing	0 (0%)	3 (5.3%)	3 (3.1%)
DCR2
No	20 (48.8%)	25 (43.9%)	45 (45.9%)
Si	21 (51.2%)	29 (50.9%)	50 (51.0%)
Missing	0 (0%)	3 (5.3%)	3 (3.1%)
PFSL2m
Mean (SD)	5.84 (4.72)	5.46 (6.87)	5.62 (6.02)
Median [Min, Max]	5.29 [0.0329, 19.2]	3.09 [0.230, 35.6]	3.99 [0.0329, 35.6]
Missing	0 (0%)	2 (3.5%)	2 (2.0%)

## Warning in ModuleReturnVarsExist(vars, data): The data frame does not have:
## OSL2fu3 OSL2fu0 Dropped

EpocaIO
	PreIO	PosIO	p
n	41	57
N.ciclos22 (%)			0.485
1-3	17 (42.5)	19 (35.2)
4-6	19 (47.5)	25 (46.3)
>6	4 (10.0)	10 (18.5)
Respuesta2 (%)			0.891
EE	8 (19.5)	14 (25.9)
PD	20 (48.8)	25 (46.3)
RC	4 ( 9.8)	4 ( 7.4)
RP	9 (22.0)	11 (20.4)
ORR2 = Si (%)	13 (31.7)	15 (27.8)	0.850
DCR2 = Si (%)	21 (51.2)	29 (53.7)	0.974
OSL2m (mean (SD))	20.58 (34.43)	9.28 (8.95)	0.022
PFSL2m (mean (SD))	5.84 (4.72)	5.46 (6.87)	0.763
OSL2fu2 = OS ≥2y (%)	7 (17.1)	4 ( 7.3)	0.243

Respuesta según tratamiento L2: all categories

All L2

	CBCDA-based (N=20)	CDDP-based (N=19)	IO (N=33)	QT no-platino (N=21)	Target (N=5)	Total (N=98)
Respuesta a 2º linea
EE	8 (40.0%)	3 (15.8%)	5 (15.2%)	5 (23.8%)	1 (20.0%)	22 (22.4%)
PD	5 (25.0%)	5 (26.3%)	21 (63.6%)	13 (61.9%)	1 (20.0%)	45 (45.9%)
RC	2 (10.0%)	3 (15.8%)	1 (3.0%)	2 (9.5%)	0 (0%)	8 (8.2%)
RP	5 (25.0%)	8 (42.1%)	3 (9.1%)	1 (4.8%)	3 (60.0%)	20 (20.4%)
Missing	0 (0%)	0 (0%)	3 (9.1%)	0 (0%)	0 (0%)	3 (3.1%)
ORR2
No	13 (65.0%)	8 (42.1%)	26 (78.8%)	18 (85.7%)	2 (40.0%)	67 (68.4%)
Si	7 (35.0%)	11 (57.9%)	4 (12.1%)	3 (14.3%)	3 (60.0%)	28 (28.6%)
Missing	0 (0%)	0 (0%)	3 (9.1%)	0 (0%)	0 (0%)	3 (3.1%)
DCR2
No	5 (25.0%)	5 (26.3%)	21 (63.6%)	13 (61.9%)	1 (20.0%)	45 (45.9%)
Si	15 (75.0%)	14 (73.7%)	9 (27.3%)	8 (38.1%)	4 (80.0%)	50 (51.0%)
Missing	0 (0%)	0 (0%)	3 (9.1%)	0 (0%)	0 (0%)	3 (3.1%)
OSL2fu1
OS <1y	14 (70.0%)	8 (42.1%)	25 (75.8%)	15 (71.4%)	3 (60.0%)	65 (66.3%)
OS ≥1y	6 (30.0%)	10 (52.6%)	7 (21.2%)	6 (28.6%)	2 (40.0%)	31 (31.6%)
Missing	0 (0%)	1 (5.3%)	1 (3.0%)	0 (0%)	0 (0%)	2 (2.0%)
OSL2fu2
OS <2y	18 (90.0%)	14 (73.7%)	31 (93.9%)	18 (85.7%)	4 (80.0%)	85 (86.7%)
OS ≥2y	2 (10.0%)	4 (21.1%)	1 (3.0%)	3 (14.3%)	1 (20.0%)	11 (11.2%)
Missing	0 (0%)	1 (5.3%)	1 (3.0%)	0 (0%)	0 (0%)	2 (2.0%)
PFSL2fu1
PFSL2 <1y	17 (85.0%)	13 (68.4%)	30 (90.9%)	20 (95.2%)	4 (80.0%)	84 (85.7%)
PFSL2 ≥1y	3 (15.0%)	5 (26.3%)	2 (6.1%)	1 (4.8%)	1 (20.0%)	12 (12.2%)
Missing	0 (0%)	1 (5.3%)	1 (3.0%)	0 (0%)	0 (0%)	2 (2.0%)
PFSL2fu2
PFSL2 <2y	19 (95.0%)	18 (94.7%)	31 (93.9%)	21 (100%)	5 (100%)	94 (95.9%)
PFSL2 ≥2y	1 (5.0%)	0 (0%)	1 (3.0%)	0 (0%)	0 (0%)	2 (2.0%)
Missing	0 (0%)	1 (5.3%)	1 (3.0%)	0 (0%)	0 (0%)	2 (2.0%)

Pre-IO L2

	CBCDA-based (N=11)	CDDP-based (N=13)	QT no-platino (N=16)	Target (N=1)	Total (N=90)
Respuesta2
EE	4 (36.4%)	1 (7.7%)	3 (18.8%)	0 (0%)	8 (8.9%)
PD	4 (36.4%)	5 (38.5%)	10 (62.5%)	1 (100%)	20 (22.2%)
RC	1 (9.1%)	1 (7.7%)	2 (12.5%)	0 (0%)	4 (4.4%)
RP	2 (18.2%)	6 (46.2%)	1 (6.3%)	0 (0%)	9 (10.0%)
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	49 (54.4%)
ORR2
No	8 (72.7%)	6 (46.2%)	13 (81.3%)	1 (100%)	28 (31.1%)
Si	3 (27.3%)	7 (53.8%)	3 (18.8%)	0 (0%)	13 (14.4%)
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	49 (54.4%)
DCR2
No	4 (36.4%)	5 (38.5%)	10 (62.5%)	1 (100%)	20 (22.2%)
Si	7 (63.6%)	8 (61.5%)	6 (37.5%)	0 (0%)	21 (23.3%)
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	49 (54.4%)

Pos-IO L2

	CBCDA-based (N=9)	CDDP-based (N=6)	IO (N=33)	QT no-platino (N=5)	Target (N=4)	Total (N=116)
Respuesta2
EE	4 (44.4%)	2 (33.3%)	5 (15.2%)	2 (40.0%)	1 (25.0%)	14 (12.1%)
PD	1 (11.1%)	0 (0%)	21 (63.6%)	3 (60.0%)	0 (0%)	25 (21.6%)
RC	1 (11.1%)	2 (33.3%)	1 (3.0%)	0 (0%)	0 (0%)	4 (3.4%)
RP	3 (33.3%)	2 (33.3%)	3 (9.1%)	0 (0%)	3 (75.0%)	11 (9.5%)
Missing	0 (0%)	0 (0%)	3 (9.1%)	0 (0%)	0 (0%)	62 (53.4%)
ORR2
No	5 (55.6%)	2 (33.3%)	26 (78.8%)	5 (100%)	1 (25.0%)	39 (33.6%)
Si	4 (44.4%)	4 (66.7%)	4 (12.1%)	0 (0%)	3 (75.0%)	15 (12.9%)
Missing	0 (0%)	0 (0%)	3 (9.1%)	0 (0%)	0 (0%)	62 (53.4%)
DCR2
No	1 (11.1%)	0 (0%)	21 (63.6%)	3 (60.0%)	0 (0%)	25 (21.6%)
Si	8 (88.9%)	6 (100%)	9 (27.3%)	2 (40.0%)	4 (100%)	29 (25.0%)
Missing	0 (0%)	0 (0%)	3 (9.1%)	0 (0%)	0 (0%)	62 (53.4%)

Respuesta según tratamiento L2: platinum

All L2

	IO (N=33)	Platino (N=39)	QT no-platino (N=21)	Target (N=5)	Total (N=98)
Respuesta a 2º linea
EE	5 (15.2%)	11 (28.2%)	5 (23.8%)	1 (20.0%)	22 (22.4%)
PD	21 (63.6%)	10 (25.6%)	13 (61.9%)	1 (20.0%)	45 (45.9%)
RC	1 (3.0%)	5 (12.8%)	2 (9.5%)	0 (0%)	8 (8.2%)
RP	3 (9.1%)	13 (33.3%)	1 (4.8%)	3 (60.0%)	20 (20.4%)
Missing	3 (9.1%)	0 (0%)	0 (0%)	0 (0%)	3 (3.1%)
ORR2
No	26 (78.8%)	21 (53.8%)	18 (85.7%)	2 (40.0%)	67 (68.4%)
Si	4 (12.1%)	18 (46.2%)	3 (14.3%)	3 (60.0%)	28 (28.6%)
Missing	3 (9.1%)	0 (0%)	0 (0%)	0 (0%)	3 (3.1%)
DCR2
No	21 (63.6%)	10 (25.6%)	13 (61.9%)	1 (20.0%)	45 (45.9%)
Si	9 (27.3%)	29 (74.4%)	8 (38.1%)	4 (80.0%)	50 (51.0%)
Missing	3 (9.1%)	0 (0%)	0 (0%)	0 (0%)	3 (3.1%)
OSL2fu1
OS <1y	25 (75.8%)	22 (56.4%)	15 (71.4%)	3 (60.0%)	65 (66.3%)
OS ≥1y	7 (21.2%)	16 (41.0%)	6 (28.6%)	2 (40.0%)	31 (31.6%)
Missing	1 (3.0%)	1 (2.6%)	0 (0%)	0 (0%)	2 (2.0%)
OSL2fu2
OS <2y	31 (93.9%)	32 (82.1%)	18 (85.7%)	4 (80.0%)	85 (86.7%)
OS ≥2y	1 (3.0%)	6 (15.4%)	3 (14.3%)	1 (20.0%)	11 (11.2%)
Missing	1 (3.0%)	1 (2.6%)	0 (0%)	0 (0%)	2 (2.0%)
PFSL2fu1
PFSL2 <1y	30 (90.9%)	30 (76.9%)	20 (95.2%)	4 (80.0%)	84 (85.7%)
PFSL2 ≥1y	2 (6.1%)	8 (20.5%)	1 (4.8%)	1 (20.0%)	12 (12.2%)
Missing	1 (3.0%)	1 (2.6%)	0 (0%)	0 (0%)	2 (2.0%)
PFSL2fu2
PFSL2 <2y	31 (93.9%)	37 (94.9%)	21 (100%)	5 (100%)	94 (95.9%)
PFSL2 ≥2y	1 (3.0%)	1 (2.6%)	0 (0%)	0 (0%)	2 (2.0%)
Missing	1 (3.0%)	1 (2.6%)	0 (0%)	0 (0%)	2 (2.0%)

Pre-IO L2

	Platino (N=24)	QT no-platino (N=16)	Target (N=1)	Total (N=90)
Respuesta2
EE	5 (20.8%)	3 (18.8%)	0 (0%)	8 (8.9%)
PD	9 (37.5%)	10 (62.5%)	1 (100%)	20 (22.2%)
RC	2 (8.3%)	2 (12.5%)	0 (0%)	4 (4.4%)
RP	8 (33.3%)	1 (6.3%)	0 (0%)	9 (10.0%)
Missing	0 (0%)	0 (0%)	0 (0%)	49 (54.4%)
ORR2
No	14 (58.3%)	13 (81.3%)	1 (100%)	28 (31.1%)
Si	10 (41.7%)	3 (18.8%)	0 (0%)	13 (14.4%)
Missing	0 (0%)	0 (0%)	0 (0%)	49 (54.4%)
DCR2
No	9 (37.5%)	10 (62.5%)	1 (100%)	20 (22.2%)
Si	15 (62.5%)	6 (37.5%)	0 (0%)	21 (23.3%)
Missing	0 (0%)	0 (0%)	0 (0%)	49 (54.4%)

Pos-IO L2

	IO (N=33)	Platino (N=15)	QT no-platino (N=5)	Target (N=4)	Total (N=116)
Respuesta2
EE	5 (15.2%)	6 (40.0%)	2 (40.0%)	1 (25.0%)	14 (12.1%)
PD	21 (63.6%)	1 (6.7%)	3 (60.0%)	0 (0%)	25 (21.6%)
RC	1 (3.0%)	3 (20.0%)	0 (0%)	0 (0%)	4 (3.4%)
RP	3 (9.1%)	5 (33.3%)	0 (0%)	3 (75.0%)	11 (9.5%)
Missing	3 (9.1%)	0 (0%)	0 (0%)	0 (0%)	62 (53.4%)
ORR2
No	26 (78.8%)	7 (46.7%)	5 (100%)	1 (25.0%)	39 (33.6%)
Si	4 (12.1%)	8 (53.3%)	0 (0%)	3 (75.0%)	15 (12.9%)
Missing	3 (9.1%)	0 (0%)	0 (0%)	0 (0%)	62 (53.4%)
DCR2
No	21 (63.6%)	1 (6.7%)	3 (60.0%)	0 (0%)	25 (21.6%)
Si	9 (27.3%)	14 (93.3%)	2 (40.0%)	4 (100%)	29 (25.0%)
Missing	3 (9.1%)	0 (0%)	0 (0%)	0 (0%)	62 (53.4%)

Tratamiento de 2da linea

	CBCDA-based (N=11)	CDDP-based (N=13)	QT no-platino (N=16)	Target (N=1)	Total (N=90)
Segunda.linea
CBCDA/GEM	9 (81.8%)	0 (0%)	0 (0%)	0 (0%)	9 (10.0%)
CBCDA/TAXOL	2 (18.2%)	0 (0%)	0 (0%)	0 (0%)	2 (2.2%)
CDDP	0 (0%)	1 (7.7%)	0 (0%)	0 (0%)	1 (1.1%)
CDDP/GEM	0 (0%)	5 (38.5%)	0 (0%)	0 (0%)	5 (5.6%)
HDMI-VAC	0 (0%)	1 (7.7%)	0 (0%)	0 (0%)	1 (1.1%)
MVAC	0 (0%)	6 (46.2%)	0 (0%)	0 (0%)	6 (6.7%)
CABACITAXEL	0 (0%)	0 (0%)	3 (18.8%)	0 (0%)	3 (3.3%)
DOCETAXEL	0 (0%)	0 (0%)	1 (6.3%)	0 (0%)	1 (1.1%)
GEM	0 (0%)	0 (0%)	5 (31.3%)	0 (0%)	5 (5.6%)
GEM/TAXOL	0 (0%)	0 (0%)	3 (18.8%)	0 (0%)	3 (3.3%)
TAXOL	0 (0%)	0 (0%)	2 (12.5%)	0 (0%)	2 (2.2%)
VINFLUBIA	0 (0%)	0 (0%)	1 (6.3%)	0 (0%)	1 (1.1%)
VP16	0 (0%)	0 (0%)	1 (6.3%)	0 (0%)	1 (1.1%)
DOVITINIB	0 (0%)	0 (0%)	0 (0%)	1 (100%)	1 (1.1%)
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	49 (54.4%)

	CBCDA-based (N=9)	CDDP-based (N=6)	IO (N=33)	QT no-platino (N=5)	Target (N=4)	Total (N=116)
Segunda.linea
CBCDA/GEM	9 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	9 (7.8%)
CDDP/GEM	0 (0%)	6 (100%)	0 (0%)	0 (0%)	0 (0%)	6 (5.2%)
ATEZO	0 (0%)	0 (0%)	18 (54.5%)	0 (0%)	0 (0%)	18 (15.5%)
DURVA/TREME	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	0 (0%)	1 (0.9%)
DURVA/VISTUSERTIB	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	0 (0%)	1 (0.9%)
NIVO/IPI	0 (0%)	0 (0%)	2 (6.1%)	0 (0%)	0 (0%)	2 (1.7%)
OLAPARIB/DURVA	0 (0%)	0 (0%)	3 (9.1%)	0 (0%)	0 (0%)	3 (2.6%)
PEMBRO	0 (0%)	0 (0%)	4 (12.1%)	0 (0%)	0 (0%)	4 (3.4%)
PEMBRO/EPACADOSTAT	0 (0%)	0 (0%)	4 (12.1%)	0 (0%)	0 (0%)	4 (3.4%)
GEM	0 (0%)	0 (0%)	0 (0%)	1 (20.0%)	0 (0%)	1 (0.9%)
GEM/TAXOL	0 (0%)	0 (0%)	0 (0%)	3 (60.0%)	0 (0%)	3 (2.6%)
TAXOL	0 (0%)	0 (0%)	0 (0%)	1 (20.0%)	0 (0%)	1 (0.9%)
AFATINIB	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (25.0%)	1 (0.9%)
ERDAFATINIB	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (50.0%)	2 (1.7%)
TAXOL/DOVITI	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (25.0%)	1 (0.9%)
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	59 (50.9%)

	Platino (N=24)	QT no-platino (N=16)	Target (N=1)	Total (N=90)
Segunda.linea
CBCDA/GEM	9 (37.5%)	0 (0%)	0 (0%)	9 (10.0%)
CBCDA/TAXOL	2 (8.3%)	0 (0%)	0 (0%)	2 (2.2%)
CDDP	1 (4.2%)	0 (0%)	0 (0%)	1 (1.1%)
CDDP/GEM	5 (20.8%)	0 (0%)	0 (0%)	5 (5.6%)
HDMI-VAC	1 (4.2%)	0 (0%)	0 (0%)	1 (1.1%)
MVAC	6 (25.0%)	0 (0%)	0 (0%)	6 (6.7%)
CABACITAXEL	0 (0%)	3 (18.8%)	0 (0%)	3 (3.3%)
DOCETAXEL	0 (0%)	1 (6.3%)	0 (0%)	1 (1.1%)
GEM	0 (0%)	5 (31.3%)	0 (0%)	5 (5.6%)
GEM/TAXOL	0 (0%)	3 (18.8%)	0 (0%)	3 (3.3%)
TAXOL	0 (0%)	2 (12.5%)	0 (0%)	2 (2.2%)
VINFLUBIA	0 (0%)	1 (6.3%)	0 (0%)	1 (1.1%)
VP16	0 (0%)	1 (6.3%)	0 (0%)	1 (1.1%)
DOVITINIB	0 (0%)	0 (0%)	1 (100%)	1 (1.1%)
Missing	0 (0%)	0 (0%)	0 (0%)	49 (54.4%)

	IO (N=33)	Platino (N=15)	QT no-platino (N=5)	Target (N=4)	Total (N=116)
Segunda.linea
ATEZO	18 (54.5%)	0 (0%)	0 (0%)	0 (0%)	18 (15.5%)
DURVA/TREME	1 (3.0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.9%)
DURVA/VISTUSERTIB	1 (3.0%)	0 (0%)	0 (0%)	0 (0%)	1 (0.9%)
NIVO/IPI	2 (6.1%)	0 (0%)	0 (0%)	0 (0%)	2 (1.7%)
OLAPARIB/DURVA	3 (9.1%)	0 (0%)	0 (0%)	0 (0%)	3 (2.6%)
PEMBRO	4 (12.1%)	0 (0%)	0 (0%)	0 (0%)	4 (3.4%)
PEMBRO/EPACADOSTAT	4 (12.1%)	0 (0%)	0 (0%)	0 (0%)	4 (3.4%)
CBCDA/GEM	0 (0%)	9 (60.0%)	0 (0%)	0 (0%)	9 (7.8%)
CDDP/GEM	0 (0%)	6 (40.0%)	0 (0%)	0 (0%)	6 (5.2%)
GEM	0 (0%)	0 (0%)	1 (20.0%)	0 (0%)	1 (0.9%)
GEM/TAXOL	0 (0%)	0 (0%)	3 (60.0%)	0 (0%)	3 (2.6%)
TAXOL	0 (0%)	0 (0%)	1 (20.0%)	0 (0%)	1 (0.9%)
AFATINIB	0 (0%)	0 (0%)	0 (0%)	1 (25.0%)	1 (0.9%)
ERDAFATINIB	0 (0%)	0 (0%)	0 (0%)	2 (50.0%)	2 (1.7%)
TAXOL/DOVITI	0 (0%)	0 (0%)	0 (0%)	1 (25.0%)	1 (0.9%)
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	59 (50.9%)

============================================================================

Overal survival L2

============================================================================

OS L2 Todos Pre vs Pos

## Call: survfit(formula = Surv(OSL2m, Muerto) ~ EpocaIO, data = dbl2, 
##     type = "kaplan-meier")
## 
##    2 observations deleted due to missingness 
##                n events median 0.95LCL 0.95UCL
## EpocaIO=PreIO 41     40  11.33    8.51    15.5
## EpocaIO=PosIO 55     38   8.21    7.36    11.7

## Call:
## survdiff(formula = Surv(OSL2m, Muerto) ~ EpocaIO, data = dbl2)
## 
## n=96, 2 observations deleted due to missingness.
## 
##                N Observed Expected (O-E)^2/E (O-E)^2/V
## EpocaIO=PreIO 41       40     42.8     0.179     0.422
## EpocaIO=PosIO 55       38     35.2     0.218     0.422
## 
##  Chisq= 0.4  on 1 degrees of freedom, p= 0.5

Pre IO

## Call: survfit(formula = Surv(OSL2m, Muerto) ~ L2Tx1, data = dbIO0, 
##     type = "kaplan-meier")
## 
##    49 observations deleted due to missingness 
##                      n events median 0.95LCL 0.95UCL
## L2Tx1=Platino       24     23  13.83    8.51    19.5
## L2Tx1=QT no-platino 16     16   9.18    2.07    23.2
## L2Tx1=Target         1      1  12.45      NA      NA

## Call: survfit(formula = Surv(OSL2m, Muerto) ~ L2Tx, data = dbIO0, type = "kaplan-meier")
## 
##    49 observations deleted due to missingness 
##                     n events median 0.95LCL 0.95UCL
## L2Tx=CBCDA-based   11     11   8.51    5.16      NA
## L2Tx=CDDP-based    13     12  15.70   13.80      NA
## L2Tx=QT no-platino 16     16   9.18    2.07    23.2
## L2Tx=Target         1      1  12.45      NA      NA

Pos IO

## Call: survfit(formula = Surv(OSL2m, Muerto) ~ L2Tx1, data = dbIO1, 
##     type = "kaplan-meier")
## 
##    61 observations deleted due to missingness 
##                      n events median 0.95LCL 0.95UCL
## L2Tx1=IO            32     22   7.82    4.99    15.3
## L2Tx1=Platino       14     10  10.78    8.21      NA
## L2Tx1=QT no-platino  5      5   5.29    3.68      NA
## L2Tx1=Target         4      1   7.52    7.52      NA

## Call: survfit(formula = Surv(OSL2m, Muerto) ~ L2Tx, data = dbIO1, type = "kaplan-meier")
## 
##    61 observations deleted due to missingness 
##                     n events median 0.95LCL 0.95UCL
## L2Tx=CBCDA-based    9      7  11.30    8.21      NA
## L2Tx=CDDP-based     5      3   9.79    7.36      NA
## L2Tx=IO            32     22   7.82    4.99    15.3
## L2Tx=QT no-platino  5      5   5.29    3.68      NA
## L2Tx=Target         4      1   7.52    7.52      NA

============================================================================

Progresion Free Survival L2

============================================================================

Todos

## Call: survfit(formula = Surv(PFSL2m, PFS2) ~ L2Tx, data = dbl2, type = "kaplan-meier")
## 
##    2 observations deleted due to missingness 
##                     n events median 0.95LCL 0.95UCL
## L2Tx=CBCDA-based   20     19   5.31    4.27    9.82
## L2Tx=CDDP-based    18     16   5.75    4.76   14.95
## L2Tx=IO            32     26   2.46    2.00    4.63
## L2Tx=QT no-platino 21     21   2.86    1.54    7.52
## L2Tx=Target         5      3   6.70    5.59      NA

## Call: survfit(formula = Surv(PFSL2m, PFS2) ~ L2Tx1, data = dbl2, type = "kaplan-meier")
## 
##    2 observations deleted due to missingness 
##                      n events median 0.95LCL 0.95UCL
## L2Tx1=IO            32     26   2.46    2.00    4.63
## L2Tx1=Platino       38     35   5.45    4.76    8.18
## L2Tx1=QT no-platino 21     21   2.86    1.54    7.52
## L2Tx1=Target         5      3   6.70    5.59      NA

## Call: survfit(formula = Surv(PFSL2m, PFS2) ~ L2, data = dbl2, type = "kaplan-meier")
## 
##    2 observations deleted due to missingness 
##       n events median 0.95LCL 0.95UCL
## [1,] 96     85   4.44    3.25    5.45

Todos Pre vs Pos IO

## Call: survfit(formula = Surv(PFSL2m, PFS2) ~ EpocaIO, data = dbl2, 
##     type = "kaplan-meier")
## 
##    2 observations deleted due to missingness 
##                n events median 0.95LCL 0.95UCL
## EpocaIO=PreIO 41     41   5.29    3.42    6.05
## EpocaIO=PosIO 55     44   3.61    2.46    5.59

## Call:
## survdiff(formula = Surv(PFSL2m, PFS2) ~ EpocaIO, data = dbl2)
## 
## n=96, 2 observations deleted due to missingness.
## 
##                N Observed Expected (O-E)^2/E (O-E)^2/V
## EpocaIO=PreIO 41       41       40    0.0228    0.0452
## EpocaIO=PosIO 55       44       45    0.0203    0.0452
## 
##  Chisq= 0  on 1 degrees of freedom, p= 0.8

Pre IO

## Call: survfit(formula = Surv(PFSL2m, PFS2) ~ L2Tx, data = dbIO0, type = "kaplan-meier")
## 
##    49 observations deleted due to missingness 
##                     n events median 0.95LCL 0.95UCL
## L2Tx=CBCDA-based   11     11   5.29    3.42      NA
## L2Tx=CDDP-based    13     13   5.75    3.12      NA
## L2Tx=QT no-platino 16     16   3.61    2.04    7.82
## L2Tx=Target         1      1   6.70      NA      NA

## Call: survfit(formula = Surv(PFSL2m, PFS2) ~ L2Tx1, data = dbIO0, type = "kaplan-meier")
## 
##    49 observations deleted due to missingness 
##                      n events median 0.95LCL 0.95UCL
## L2Tx1=Platino       24     24   5.39    3.81    9.82
## L2Tx1=QT no-platino 16     16   3.61    2.04    7.82
## L2Tx1=Target         1      1   6.70      NA      NA

Pos IO

## Call: survfit(formula = Surv(PFSL2m, PFS2) ~ L2Tx, data = dbIO1, type = "kaplan-meier")
## 
##    61 observations deleted due to missingness 
##                     n events median 0.95LCL 0.95UCL
## L2Tx=CBCDA-based    9      8   5.65    4.44      NA
## L2Tx=CDDP-based     5      3   8.18    4.76      NA
## L2Tx=IO            32     26   2.46    2.00    4.63
## L2Tx=QT no-platino  5      5   1.54    1.45      NA
## L2Tx=Target         4      2   8.87    5.59      NA

## Call: survfit(formula = Surv(PFSL2m, PFS2) ~ L2Tx1, data = dbIO1, type = "kaplan-meier")
## 
##    61 observations deleted due to missingness 
##                      n events median 0.95LCL 0.95UCL
## L2Tx1=IO            32     26   2.46    2.00    4.63
## L2Tx1=Platino       14     11   5.65    4.44      NA
## L2Tx1=QT no-platino  5      5   1.54    1.45      NA
## L2Tx1=Target         4      2   8.87    5.59      NA

============================================================================

Análisis Tercera Linea

============================================================================

Resumen

	PreIO (N=25)	PosIO (N=29)	Total (N=54)
Tratamiento de 3º linea
CBCDA-based	5 (20.0%)	4 (13.8%)	9 (16.7%)
CDDP-based	1 (4.0%)	1 (3.4%)	2 (3.7%)
IO	0 (0%)	5 (17.2%)	5 (9.3%)
QT no-platino	19 (76.0%)	9 (31.0%)	28 (51.9%)
Target	0 (0%)	10 (34.5%)	10 (18.5%)
Nro. Ciclos de 3º linea
1-3	11 (44.0%)	17 (58.6%)	28 (51.9%)
4-6	10 (40.0%)	7 (24.1%)	17 (31.5%)
>6	4 (16.0%)	4 (13.8%)	8 (14.8%)
Missing	0 (0%)	1 (3.4%)	1 (1.9%)
Respuesta a 3º linea
EE	3 (12.0%)	2 (6.9%)	5 (9.3%)
PD	13 (52.0%)	18 (62.1%)	31 (57.4%)
RC	1 (4.0%)	0 (0%)	1 (1.9%)
RP	7 (28.0%)	7 (24.1%)	14 (25.9%)
Missing	1 (4.0%)	2 (6.9%)	3 (5.6%)
OSL3m
Mean (SD)	17.2 (34.4)	4.88 (4.30)	10.6 (24.1)
Median [Min, Max]	7.52 [0.460, 147]	3.45 [0.230, 15.9]	5.16 [0.230, 147]
ORR3
No	16 (64.0%)	20 (69.0%)	36 (66.7%)
Si	8 (32.0%)	7 (24.1%)	15 (27.8%)
Missing	1 (4.0%)	2 (6.9%)	3 (5.6%)
DCR3
No	13 (52.0%)	18 (62.1%)	31 (57.4%)
Si	11 (44.0%)	9 (31.0%)	20 (37.0%)
Missing	1 (4.0%)	2 (6.9%)	3 (5.6%)
PFSL3m
Mean (SD)	15.3 (34.7)	3.88 (3.29)	9.18 (24.2)
Median [Min, Max]	5.75 [0.460, 147]	2.76 [0.230, 12.4]	3.86 [0.230, 147]

## Warning in ModuleReturnVarsExist(vars, data): The data frame does not have:
## OSL3fu3 OSL3fu0 Dropped

EpocaIO
	PreIO	PosIO	p
n	25	29
N.ciclos32 (%)			0.438
1-3	11 (44.0)	17 (60.7)
4-6	10 (40.0)	7 (25.0)
>6	4 (16.0)	4 (14.3)
Respuesta3 (%)			0.607
EE	3 (12.5)	2 ( 7.4)
PD	13 (54.2)	18 (66.7)
RC	1 ( 4.2)	0 ( 0.0)
RP	7 (29.2)	7 (25.9)
ORR3 = Si (%)	8 (33.3)	7 (25.9)	0.786
DCR3 = Si (%)	11 (45.8)	9 (33.3)	0.532
OSL3m (mean (SD))	17.17 (34.37)	4.88 (4.30)	0.061
PFSL3m (mean (SD))	15.33 (34.73)	3.88 (3.29)	0.083
OSL3fu2 = OS ≥2y (%)	2 ( 8.0)	0 ( 0.0)	0.407

Respuesta según tratamiento L3

All L3: all categories

	CBCDA-based (N=9)	CDDP-based (N=2)	IO (N=5)	QT no-platino (N=28)	Target (N=10)	Total (N=54)
Respuesta a 3º linea
EE	1 (11.1%)	1 (50.0%)	1 (20.0%)	2 (7.1%)	0 (0%)	5 (9.3%)
PD	3 (33.3%)	0 (0%)	3 (60.0%)	18 (64.3%)	7 (70.0%)	31 (57.4%)
RP	4 (44.4%)	1 (50.0%)	1 (20.0%)	5 (17.9%)	3 (30.0%)	14 (25.9%)
RC	0 (0%)	0 (0%)	0 (0%)	1 (3.6%)	0 (0%)	1 (1.9%)
Missing	1 (11.1%)	0 (0%)	0 (0%)	2 (7.1%)	0 (0%)	3 (5.6%)
ORR3
No	4 (44.4%)	1 (50.0%)	4 (80.0%)	20 (71.4%)	7 (70.0%)	36 (66.7%)
Si	4 (44.4%)	1 (50.0%)	1 (20.0%)	6 (21.4%)	3 (30.0%)	15 (27.8%)
Missing	1 (11.1%)	0 (0%)	0 (0%)	2 (7.1%)	0 (0%)	3 (5.6%)
DCR3
No	3 (33.3%)	0 (0%)	3 (60.0%)	18 (64.3%)	7 (70.0%)	31 (57.4%)
Si	5 (55.6%)	2 (100%)	2 (40.0%)	8 (28.6%)	3 (30.0%)	20 (37.0%)
Missing	1 (11.1%)	0 (0%)	0 (0%)	2 (7.1%)	0 (0%)	3 (5.6%)

Pre-IO L3

	CBCDA-based (N=5)	CDDP-based (N=1)	QT no-platino (N=19)	Total (N=90)
Respuesta3
EE	1 (20.0%)	0 (0%)	2 (10.5%)	3 (3.3%)
PD	3 (60.0%)	0 (0%)	10 (52.6%)	13 (14.4%)
RP	1 (20.0%)	1 (100%)	5 (26.3%)	7 (7.8%)
RC	0 (0%)	0 (0%)	1 (5.3%)	1 (1.1%)
Missing	0 (0%)	0 (0%)	1 (5.3%)	66 (73.3%)
ORR3
No	4 (80.0%)	0 (0%)	12 (63.2%)	16 (17.8%)
Si	1 (20.0%)	1 (100%)	6 (31.6%)	8 (8.9%)
Missing	0 (0%)	0 (0%)	1 (5.3%)	66 (73.3%)
DCR3
No	3 (60.0%)	0 (0%)	10 (52.6%)	13 (14.4%)
Si	2 (40.0%)	1 (100%)	8 (42.1%)	11 (12.2%)
Missing	0 (0%)	0 (0%)	1 (5.3%)	66 (73.3%)

Pos-IO L3

	CBCDA-based (N=4)	CDDP-based (N=1)	IO (N=5)	QT no-platino (N=9)	Target (N=10)	Total (N=116)
Respuesta3
RP	3 (75.0%)	0 (0%)	1 (20.0%)	0 (0%)	3 (30.0%)	7 (6.0%)
EE	0 (0%)	1 (100%)	1 (20.0%)	0 (0%)	0 (0%)	2 (1.7%)
PD	0 (0%)	0 (0%)	3 (60.0%)	8 (88.9%)	7 (70.0%)	18 (15.5%)
Missing	1 (25.0%)	0 (0%)	0 (0%)	1 (11.1%)	0 (0%)	89 (76.7%)
ORR3
No	0 (0%)	1 (100%)	4 (80.0%)	8 (88.9%)	7 (70.0%)	20 (17.2%)
Si	3 (75.0%)	0 (0%)	1 (20.0%)	0 (0%)	3 (30.0%)	7 (6.0%)
Missing	1 (25.0%)	0 (0%)	0 (0%)	1 (11.1%)	0 (0%)	89 (76.7%)
DCR3
No	0 (0%)	0 (0%)	3 (60.0%)	8 (88.9%)	7 (70.0%)	18 (15.5%)
Si	3 (75.0%)	1 (100%)	2 (40.0%)	0 (0%)	3 (30.0%)	9 (7.8%)
Missing	1 (25.0%)	0 (0%)	0 (0%)	1 (11.1%)	0 (0%)	89 (76.7%)

All L3: platinum categoris

	IO (N=5)	Platino (N=11)	QT no-platino (N=28)	Target (N=10)	Total (N=54)
Respuesta a 3º linea
EE	1 (20.0%)	2 (18.2%)	2 (7.1%)	0 (0%)	5 (9.3%)
PD	3 (60.0%)	3 (27.3%)	18 (64.3%)	7 (70.0%)	31 (57.4%)
RP	1 (20.0%)	5 (45.5%)	5 (17.9%)	3 (30.0%)	14 (25.9%)
RC	0 (0%)	0 (0%)	1 (3.6%)	0 (0%)	1 (1.9%)
Missing	0 (0%)	1 (9.1%)	2 (7.1%)	0 (0%)	3 (5.6%)
ORR3
No	4 (80.0%)	5 (45.5%)	20 (71.4%)	7 (70.0%)	36 (66.7%)
Si	1 (20.0%)	5 (45.5%)	6 (21.4%)	3 (30.0%)	15 (27.8%)
Missing	0 (0%)	1 (9.1%)	2 (7.1%)	0 (0%)	3 (5.6%)
DCR3
No	3 (60.0%)	3 (27.3%)	18 (64.3%)	7 (70.0%)	31 (57.4%)
Si	2 (40.0%)	7 (63.6%)	8 (28.6%)	3 (30.0%)	20 (37.0%)
Missing	0 (0%)	1 (9.1%)	2 (7.1%)	0 (0%)	3 (5.6%)

Pre-IO L3

	Platino (N=6)	QT no-platino (N=19)	Total (N=90)
Respuesta3
EE	1 (16.7%)	2 (10.5%)	3 (3.3%)
PD	3 (50.0%)	10 (52.6%)	13 (14.4%)
RP	2 (33.3%)	5 (26.3%)	7 (7.8%)
RC	0 (0%)	1 (5.3%)	1 (1.1%)
Missing	0 (0%)	1 (5.3%)	66 (73.3%)
ORR3
No	4 (66.7%)	12 (63.2%)	16 (17.8%)
Si	2 (33.3%)	6 (31.6%)	8 (8.9%)
Missing	0 (0%)	1 (5.3%)	66 (73.3%)
DCR3
No	3 (50.0%)	10 (52.6%)	13 (14.4%)
Si	3 (50.0%)	8 (42.1%)	11 (12.2%)
Missing	0 (0%)	1 (5.3%)	66 (73.3%)

Pos-IO L3

	IO (N=5)	Platino (N=5)	QT no-platino (N=9)	Target (N=10)	Total (N=116)
Respuesta3
EE	1 (20.0%)	1 (20.0%)	0 (0%)	0 (0%)	2 (1.7%)
PD	3 (60.0%)	0 (0%)	8 (88.9%)	7 (70.0%)	18 (15.5%)
RP	1 (20.0%)	3 (60.0%)	0 (0%)	3 (30.0%)	7 (6.0%)
Missing	0 (0%)	1 (20.0%)	1 (11.1%)	0 (0%)	89 (76.7%)
ORR3
No	4 (80.0%)	1 (20.0%)	8 (88.9%)	7 (70.0%)	20 (17.2%)
Si	1 (20.0%)	3 (60.0%)	0 (0%)	3 (30.0%)	7 (6.0%)
Missing	0 (0%)	1 (20.0%)	1 (11.1%)	0 (0%)	89 (76.7%)
DCR3
No	3 (60.0%)	0 (0%)	8 (88.9%)	7 (70.0%)	18 (15.5%)
Si	2 (40.0%)	4 (80.0%)	0 (0%)	3 (30.0%)	9 (7.8%)
Missing	0 (0%)	1 (20.0%)	1 (11.1%)	0 (0%)	89 (76.7%)

Tratamiento de 3ra linea

Pre-IO L3

	CBCDA-based (N=5)	CDDP-based (N=1)	QT no-platino (N=19)	Total (N=90)
Tipo.Tercera.Linea
CBCDA	2 (40.0%)	0 (0%)	0 (0%)	2 (2.2%)
CBCDA/GEM	2 (40.0%)	0 (0%)	0 (0%)	2 (2.2%)
CBCDA/TAXOL	1 (20.0%)	0 (0%)	0 (0%)	1 (1.1%)
MVAC	0 (0%)	1 (100%)	0 (0%)	1 (1.1%)
GEM	0 (0%)	0 (0%)	10 (52.6%)	10 (11.1%)
GEM/TAXOL	0 (0%)	0 (0%)	4 (21.1%)	4 (4.4%)
TAXOL	0 (0%)	0 (0%)	1 (5.3%)	1 (1.1%)
VINFLUNINA	0 (0%)	0 (0%)	4 (21.1%)	4 (4.4%)
Missing	0 (0%)	0 (0%)	0 (0%)	65 (72.2%)

	Platino (N=6)	QT no-platino (N=19)	Total (N=90)
Tipo.Tercera.Linea
CBCDA	2 (33.3%)	0 (0%)	2 (2.2%)
CBCDA/GEM	2 (33.3%)	0 (0%)	2 (2.2%)
CBCDA/TAXOL	1 (16.7%)	0 (0%)	1 (1.1%)
MVAC	1 (16.7%)	0 (0%)	1 (1.1%)
GEM	0 (0%)	10 (52.6%)	10 (11.1%)
GEM/TAXOL	0 (0%)	4 (21.1%)	4 (4.4%)
TAXOL	0 (0%)	1 (5.3%)	1 (1.1%)
VINFLUNINA	0 (0%)	4 (21.1%)	4 (4.4%)
Missing	0 (0%)	0 (0%)	65 (72.2%)

Pos-IO L3

	CBCDA-based (N=4)	CDDP-based (N=1)	IO (N=5)	QT no-platino (N=9)	Target (N=10)	Total (N=116)
Tipo.Tercera.Linea
CBCDA/GEM	4 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (3.4%)
MVAC	0 (0%)	1 (100%)	0 (0%)	0 (0%)	0 (0%)	1 (0.9%)
ATEZO	0 (0%)	0 (0%)	5 (100%)	0 (0%)	0 (0%)	5 (4.3%)
DOCETAXEL	0 (0%)	0 (0%)	0 (0%)	2 (22.2%)	0 (0%)	2 (1.7%)
DOXO	0 (0%)	0 (0%)	0 (0%)	1 (11.1%)	0 (0%)	1 (0.9%)
GEM	0 (0%)	0 (0%)	0 (0%)	2 (22.2%)	0 (0%)	2 (1.7%)
GEM/TAXOL	0 (0%)	0 (0%)	0 (0%)	2 (22.2%)	0 (0%)	2 (1.7%)
TAXOL	0 (0%)	0 (0%)	0 (0%)	2 (22.2%)	0 (0%)	2 (1.7%)
ENFORTUMAB	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (20.0%)	2 (1.7%)
RUCAPARIB	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (10.0%)	1 (0.9%)
TAXOL/TAK228	0 (0%)	0 (0%)	0 (0%)	0 (0%)	7 (70.0%)	7 (6.0%)
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	87 (75.0%)

	IO (N=5)	Platino (N=5)	QT no-platino (N=9)	Target (N=10)	Total (N=116)
Tipo.Tercera.Linea
ATEZO	5 (100%)	0 (0%)	0 (0%)	0 (0%)	5 (4.3%)
CBCDA/GEM	0 (0%)	4 (80.0%)	0 (0%)	0 (0%)	4 (3.4%)
MVAC	0 (0%)	1 (20.0%)	0 (0%)	0 (0%)	1 (0.9%)
DOCETAXEL	0 (0%)	0 (0%)	2 (22.2%)	0 (0%)	2 (1.7%)
DOXO	0 (0%)	0 (0%)	1 (11.1%)	0 (0%)	1 (0.9%)
GEM	0 (0%)	0 (0%)	2 (22.2%)	0 (0%)	2 (1.7%)
GEM/TAXOL	0 (0%)	0 (0%)	2 (22.2%)	0 (0%)	2 (1.7%)
TAXOL	0 (0%)	0 (0%)	2 (22.2%)	0 (0%)	2 (1.7%)
ENFORTUMAB	0 (0%)	0 (0%)	0 (0%)	2 (20.0%)	2 (1.7%)
RUCAPARIB	0 (0%)	0 (0%)	0 (0%)	1 (10.0%)	1 (0.9%)
TAXOL/TAK228	0 (0%)	0 (0%)	0 (0%)	7 (70.0%)	7 (6.0%)
Missing	0 (0%)	0 (0%)	0 (0%)	0 (0%)	87 (75.0%)

============================================================================

Overal survival L3

============================================================================

Todos los tratamientos

## Call: survfit(formula = Surv(OSL3m, Muerto) ~ L3Tx, data = dbl3, type = "kaplan-meier")
## 
##                     n events median 0.95LCL 0.95UCL
## L3Tx=CBCDA-based    9      6   8.51    6.83      NA
## L3Tx=CDDP-based     2      2  12.88    9.86      NA
## L3Tx=IO             5      3   4.47    3.91      NA
## L3Tx=QT no-platino 28     27   6.00    2.76    10.1
## L3Tx=Target        10     10   1.81    0.92      NA

## Call: survfit(formula = Surv(OSL3m, Muerto) ~ L3Tx1, data = dbl3, type = "kaplan-meier")
## 
##                      n events median 0.95LCL 0.95UCL
## L3Tx1=IO             5      3   4.47    3.91      NA
## L3Tx1=Platino       11      8   9.86    6.83      NA
## L3Tx1=QT no-platino 28     27   6.00    2.76    10.1
## L3Tx1=Target        10     10   1.81    0.92      NA

## Call: survfit(formula = Surv(OSL3m, Muerto) ~ L3, data = dbl3, type = "kaplan-meier")
## 
##       n events median 0.95LCL 0.95UCL
## [1,] 54     48   6.83    3.58    8.31

Pre y Post IO

## Call: survfit(formula = Surv(OSL3m, Muerto) ~ EpocaIO, data = dbl3, 
##     type = "kaplan-meier")
## 
##                n events median 0.95LCL 0.95UCL
## EpocaIO=PreIO 25     24   7.52    5.75   11.89
## EpocaIO=PosIO 29     24   3.68    2.69    7.95

Pre IO L3

## Call: survfit(formula = Surv(OSL3m, Muerto) ~ L3Tx1, data = dbIO0, 
##     type = "kaplan-meier")
## 
##    65 observations deleted due to missingness 
##                      n events median 0.95LCL 0.95UCL
## L3Tx1=Platino        6      6   7.67    3.58      NA
## L3Tx1=QT no-platino 19     18   7.52    5.75    12.4

## Call: survfit(formula = Surv(OSL3m, Muerto) ~ L3Tx, data = dbIO0, type = "kaplan-meier")
## 
##    65 observations deleted due to missingness 
##                     n events median 0.95LCL 0.95UCL
## L3Tx=CBCDA-based    5      5   6.83    3.58      NA
## L3Tx=CDDP-based     1      1   9.86      NA      NA
## L3Tx=QT no-platino 19     18   7.52    5.75    12.4

Post IO L3

## Call: survfit(formula = Surv(OSL3m, Muerto) ~ L3Tx1, data = dbIO1, 
##     type = "kaplan-meier")
## 
##    87 observations deleted due to missingness 
##                      n events median 0.95LCL 0.95UCL
## L3Tx1=IO             5      3   4.47    3.91      NA
## L3Tx1=Platino        5      2  13.37   10.84      NA
## L3Tx1=QT no-platino  9      9   2.76    1.74      NA
## L3Tx1=Target        10     10   1.81    0.92      NA

## Call: survfit(formula = Surv(OSL3m, Muerto) ~ L3Tx, data = dbIO1, type = "kaplan-meier")
## 
##    87 observations deleted due to missingness 
##                     n events median 0.95LCL 0.95UCL
## L3Tx=CBCDA-based    4      1  10.84      NA      NA
## L3Tx=CDDP-based     1      1  15.90      NA      NA
## L3Tx=IO             5      3   4.47    3.91      NA
## L3Tx=QT no-platino  9      9   2.76    1.74      NA
## L3Tx=Target        10     10   1.81    0.92      NA

============================================================================

Progresion Free Survival L3

============================================================================

Todos

## Call: survfit(formula = Surv(PFSL3m, PFS3) ~ L3Tx, data = dbl3, type = "kaplan-meier")
## 
##                     n events median 0.95LCL 0.95UCL
## L3Tx=CBCDA-based    9      6   6.83    3.58      NA
## L3Tx=CDDP-based     2      2  10.45    9.86      NA
## L3Tx=IO             5      3   3.91    2.37      NA
## L3Tx=QT no-platino 28     27   3.91    2.69    7.23
## L3Tx=Target        10     10   1.74    0.92      NA

## Call: survfit(formula = Surv(PFSL3m, PFS3) ~ L3, data = dbl3, type = "kaplan-meier")
## 
##       n events median 0.95LCL 0.95UCL
## [1,] 54     48   3.91    2.69    6.83

Todos Pre vs Pos IO

## Call: survfit(formula = Surv(PFSL3m, PFS3) ~ EpocaIO, data = dbl3, 
##     type = "kaplan-meier")
## 
##                n events median 0.95LCL 0.95UCL
## EpocaIO=PreIO 25     24   5.75    3.58    8.51
## EpocaIO=PosIO 29     24   2.91    2.27    7.06

## Call:
## survdiff(formula = Surv(PFSL3m, PFS3) ~ EpocaIO, data = dbl3)
## 
##                N Observed Expected (O-E)^2/E (O-E)^2/V
## EpocaIO=PreIO 25       24     28.8     0.803      2.15
## EpocaIO=PosIO 29       24     19.2     1.205      2.15
## 
##  Chisq= 2.1  on 1 degrees of freedom, p= 0.1

## Call: survfit(formula = Surv(OSL4m, Muerto) ~ L4Tx, data = dbl4, type = "kaplan-meier")
## 
##                   n events median 0.95LCL 0.95UCL
## L4Tx=CBCDA-based  4      4   4.04   0.953      NA
## L4Tx=DOCETAXEL    1      1   2.10      NA      NA
## L4Tx=GEM          4      4   7.87   0.756      NA
## L4Tx=GEM/OXAL     1      1   9.99      NA      NA
## L4Tx=TAXOL/GEM    1      1   4.86      NA      NA
## L4Tx=TAXOL/TAK228 1      1   2.89      NA      NA

## Call: survfit(formula = Surv(OSL4m, Muerto) ~ EpocaIO, data = dbl4, 
##     type = "kaplan-meier")
## 
##               n events median 0.95LCL 0.95UCL
## EpocaIO=PreIO 5      5   7.89    7.85      NA
## EpocaIO=PosIO 7      7   2.89    2.10      NA

============================================================================

Flujo de Lineas

============================================================================

Combinaciones de líneas Generales

##            L1Tx2         L2Tx2  n
## 1    CBCDA-based   CBCDA-based 11
## 2    CBCDA-based    CDDP-based  5
## 3    CBCDA-based            IO 21
## 4    CBCDA-based            No 49
## 5    CBCDA-based QT no-platino 12
## 6    CBCDA-based        Target  4
## 7     CDDP-based   CBCDA-based  6
## 8     CDDP-based    CDDP-based 12
## 9     CDDP-based            IO 11
## 10    CDDP-based            No 30
## 11    CDDP-based QT no-platino  6
## 12            IO   CBCDA-based  3
## 13            IO    CDDP-based  2
## 14            IO            No 13
## 15            IO QT no-platino  2
## 16            IO        Target  1
## 17            No            No 39
## 18 QT no-platino            IO  1
## 19 QT no-platino            No 16
## 20 QT no-platino QT no-platino  1

##            L2Tx2         L3Tx2   n
## 1    CBCDA-based   CBCDA-based   4
## 2    CBCDA-based            IO   1
## 3    CBCDA-based            No   9
## 4    CBCDA-based QT no-platino   4
## 5    CBCDA-based        Target   2
## 6     CDDP-based    CDDP-based   1
## 7     CDDP-based            IO   1
## 8     CDDP-based            No   6
## 9     CDDP-based QT no-platino   9
## 10    CDDP-based        Target   2
## 11            IO   CBCDA-based   3
## 12            IO    CDDP-based   1
## 13            IO            IO   1
## 14            IO            No  16
## 15            IO QT no-platino   6
## 16            IO        Target   6
## 17            No            No 147
## 18 QT no-platino   CBCDA-based   2
## 19 QT no-platino            IO   1
## 20 QT no-platino            No  11
## 21 QT no-platino QT no-platino   7
## 22        Target            IO   1
## 23        Target            No   2
## 24        Target QT no-platino   2

Combinaciones de líneas Pre-IO

##            L1Tx2         L2Tx2  n
## 1    CBCDA-based   CBCDA-based  8
## 2    CBCDA-based    CDDP-based  5
## 3    CBCDA-based            No 22
## 4    CBCDA-based QT no-platino 10
## 5    CBCDA-based        Target  1
## 6     CDDP-based   CBCDA-based  3
## 7     CDDP-based    CDDP-based  8
## 8     CDDP-based            No 17
## 9     CDDP-based QT no-platino  5
## 10 QT no-platino            No 10
## 11 QT no-platino QT no-platino  1

##            L2Tx2         L3Tx2  n
## 1    CBCDA-based   CBCDA-based  3
## 2    CBCDA-based            No  5
## 3    CBCDA-based QT no-platino  3
## 4     CDDP-based    CDDP-based  1
## 5     CDDP-based            No  3
## 6     CDDP-based QT no-platino  9
## 7             No            No 49
## 8  QT no-platino   CBCDA-based  2
## 9  QT no-platino            No  8
## 10 QT no-platino QT no-platino  6
## 11        Target QT no-platino  1

Combinaciones de líneas Post-IO

##            L1Tx2         L2Tx2  n
## 1    CBCDA-based   CBCDA-based  3
## 2    CBCDA-based            IO 21
## 3    CBCDA-based            No 27
## 4    CBCDA-based QT no-platino  2
## 5    CBCDA-based        Target  3
## 6     CDDP-based   CBCDA-based  3
## 7     CDDP-based    CDDP-based  4
## 8     CDDP-based            IO 11
## 9     CDDP-based            No 13
## 10    CDDP-based QT no-platino  1
## 11            IO   CBCDA-based  3
## 12            IO    CDDP-based  2
## 13            IO            No 13
## 14            IO QT no-platino  2
## 15            IO        Target  1
## 16 QT no-platino            IO  1
## 17 QT no-platino            No  6

##            L2Tx2         L3Tx2  n
## 1    CBCDA-based   CBCDA-based  1
## 2    CBCDA-based            IO  1
## 3    CBCDA-based            No  4
## 4    CBCDA-based QT no-platino  1
## 5    CBCDA-based        Target  2
## 6     CDDP-based            IO  1
## 7     CDDP-based            No  3
## 8     CDDP-based        Target  2
## 9             IO   CBCDA-based  3
## 10            IO    CDDP-based  1
## 11            IO            IO  1
## 12            IO            No 16
## 13            IO QT no-platino  6
## 14            IO        Target  6
## 15            No            No 59
## 16 QT no-platino            IO  1
## 17 QT no-platino            No  3
## 18 QT no-platino QT no-platino  1
## 19        Target            IO  1
## 20        Target            No  2
## 21        Target QT no-platino  1

Grafica pre-IO

Grafica post-IO

============================================================================

Restricted Mean time survival

============================================================================

RMST by Epoca

## 
## The truncation time: tau = 12  was specified. 
## 
## Restricted Mean Survival Time (RMST) by arm 
##                Est.    se lower .95 upper .95
## RMST (arm=1) 10.094 0.313     9.481    10.707
## RMST (arm=0)  9.392 0.362     8.684    10.101
## 
## 
## Restricted Mean Time Lost (RMTL) by arm 
##               Est.    se lower .95 upper .95
## RMTL (arm=1) 1.906 0.313     1.293     2.519
## RMTL (arm=0) 2.608 0.362     1.899     3.316
## 
## 
## Between-group contrast 
##                       Est. lower .95 upper .95     p
## RMST (arm=1)-(arm=0) 0.702    -0.236     1.639 0.142
## RMST (arm=1)/(arm=0) 1.075     0.975     1.184 0.145
## RMTL (arm=1)/(arm=0) 0.731     0.480     1.114 0.145

## 
## The truncation time: tau = 24  was specified. 
## 
## Restricted Mean Survival Time (RMST) by arm 
##                Est.    se lower .95 upper .95
## RMST (arm=1) 16.194 0.798    14.630    17.757
## RMST (arm=0) 14.873 0.893    13.122    16.623
## 
## 
## Restricted Mean Time Lost (RMTL) by arm 
##               Est.    se lower .95 upper .95
## RMTL (arm=1) 7.806 0.798     6.243     9.370
## RMTL (arm=0) 9.127 0.893     7.377    10.878
## 
## 
## Between-group contrast 
##                       Est. lower .95 upper .95     p
## RMST (arm=1)-(arm=0) 1.321    -1.026     3.668 0.270
## RMST (arm=1)/(arm=0) 1.089     0.935     1.268 0.273
## RMTL (arm=1)/(arm=0) 0.855     0.648     1.129 0.269

RMST by Chemo vs IO after ICI

## 
## The truncation time: tau = 12  was specified. 
## 
## Restricted Mean Survival Time (RMST) by arm 
##                Est.    se lower .95 upper .95
## RMST (arm=1) 11.021 0.315    10.404    11.638
## RMST (arm=0)  9.109 0.519     8.092    10.126
## 
## 
## Restricted Mean Time Lost (RMTL) by arm 
##               Est.    se lower .95 upper .95
## RMTL (arm=1) 0.979 0.315     0.362     1.596
## RMTL (arm=0) 2.891 0.519     1.874     3.908
## 
## 
## Between-group contrast 
##                       Est. lower .95 upper .95     p
## RMST (arm=1)-(arm=0) 1.912     0.722     3.102 0.002
## RMST (arm=1)/(arm=0) 1.210     1.068     1.371 0.003
## RMTL (arm=1)/(arm=0) 0.339     0.164     0.697 0.003

## 
## The truncation time: tau = 24  was specified. 
## 
## Restricted Mean Survival Time (RMST) by arm 
##                Est.    se lower .95 upper .95
## RMST (arm=1) 17.695 0.942    15.849    19.541
## RMST (arm=0) 14.756 1.287    12.234    17.278
## 
## 
## Restricted Mean Time Lost (RMTL) by arm 
##               Est.    se lower .95 upper .95
## RMTL (arm=1) 6.305 0.942     4.459     8.151
## RMTL (arm=0) 9.244 1.287     6.722    11.766
## 
## 
## Between-group contrast 
##                       Est. lower .95 upper .95     p
## RMST (arm=1)-(arm=0) 2.939    -0.187     6.064 0.065
## RMST (arm=1)/(arm=0) 1.199     0.982     1.465 0.075
## RMTL (arm=1)/(arm=0) 0.682     0.457     1.018 0.061

Urothelial Cancer

TapiaJC

21/11/2022

============================================================================

============================================================================

Patients characteristics

============================================================================

============================================================================

Treated patients characteristics

============================================================================

============================================================================

Medianas de supervivencia (meses)

============================================================================

============================================================================

Median follow-up times

median follow-up overall

median follow-up survivors

median follow-up Pre-IO

median follow-up Post-IO

============================================================================

============================================================================

Análisis Primera Linea

============================================================================

============================================================================

Resumen

Respuesta L1 : all categories

All L1

Pre-IO L1

Pos-IO L1

Respuesta L1 : platinum

All L1

Pre-IO L1

Pos-IO L1

Tratamiento de 1ra linea

Pre-IO L1

Pos-IO L1

============================================================================

Overall Survival L1

============================================================================

OS L1 Todos Pre vs Pos IO

OS L1 Pre IO

OS L1 Pos IO

============================================================================

Progresion Free Survival L1

============================================================================

Pre vs Pos IO

Pre IO

Pos IO

============================================================================

============================================================================

Análisis Segunda Linea

============================================================================

============================================================================

Resumen

Respuesta según tratamiento L2: all categories

All L2

Pre-IO L2

Pos-IO L2

Respuesta según tratamiento L2: platinum

All L2

Pre-IO L2

Pos-IO L2

Tratamiento de 2da linea

============================================================================

Overal survival L2

============================================================================

OS L2 Todos Pre vs Pos

Pre IO

Pos IO

============================================================================

Progresion Free Survival L2

============================================================================

Todos

Todos Pre vs Pos IO

Pre IO

Pos IO

============================================================================

============================================================================

Análisis Tercera Linea

============================================================================